Pearson, Caroline A. published the artcileWhen the BBB goes MIA, Application In Synthesis of 169590-42-5, the publication is Proceedings of the National Academy of Sciences of the United States of America (2022), 119(19), e2204159119, database is CAplus and MEDLINE.
A review. Epidemiol. studies implicate maternal immune activation (MIA) as a risk factor for a variety of neurodevelopmental disorders. Early MIA results in BBB disruption and inflammatory responses that lead to persistent postnatal structural and cellular defects associated with MIA, rescuable by celecoxib treatment. The findings advance our understanding of the developmental origins of MIA-associated cognitive deflicits and unveil a potential therapeutic intervention for the BBB dysfunction and chronic inflammation associated with neurodevelopmental disease. In addition, the data raise the possibility that the BBB alterations induced by MIA may also contribute to other diseases associated with chronic neuroinflammation. In this regard, MIA in the setting of the SARS-CoV-2 pandemic should alert health-care providers to this potential risk, warranting careful monitoring of the offspring in infected mothers.
Proceedings of the National Academy of Sciences of the United States of America published new progress about 169590-42-5. 169590-42-5 belongs to amides-buliding-blocks, auxiliary class Sulfamide,Immunology/Inflammation,COX, name is 4-(5-(p-Tolyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide, and the molecular formula is C17H14F3N3O2S, Application In Synthesis of 169590-42-5.
Referemce:
https://en.wikipedia.org/wiki/Amide,
Amide – an overview | ScienceDirect Topics